Why Does the Type of Halogen Atom Matter for the Radiosensitizing Properties of 5-Halogen Substituted 4-Thio-2'-Deoxyuridines?


Journal

Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009

Informations de publication

Date de publication:
02 Aug 2019
Historique:
received: 17 07 2019
revised: 30 07 2019
accepted: 31 07 2019
entrez: 7 8 2019
pubmed: 7 8 2019
medline: 7 1 2020
Statut: epublish

Résumé

Radiosensitizing properties of substituted uridines are of great importance for radiotherapy. Very recently, we confirmed 5-iodo-4-thio-2'-deoxyuridine (ISdU) as an efficient agent, increasing the extent of tumor cell killing with ionizing radiation. To our surprise, a similar derivative of 4-thio-2'-deoxyuridine, 5-bromo-4-thio-2'-deoxyuridine (BrSdU), does not show radiosensitizing properties at all. In order to explain this remarkable difference, we carried out a radiolytic (stationary and pulse) and quantum chemical studies, which allowed the pathways to all radioproducts to be rationalized. In contrast to ISdU solutions, where radiolysis leads to 4-thio-2'-deoxyuridine and its dimer, no dissociative electron attachment (DEA) products were observed for BrSdU. This observation seems to explain the lack of radiosensitizing properties of BrSdU since the efficient formation of the uridine-5-yl radical, induced by electron attachment to the modified nucleoside, is suggested to be an indispensable attribute of radiosensitizing uridines. A larger activation barrier for DEA in BrSdU, as compared to ISdU, is probably responsible for the closure of DEA channel in the former system. Indeed, besides DEA, the XSdU anions may undergo competitive protonation, which makes the release of X

Identifiants

pubmed: 31382376
pii: molecules24152819
doi: 10.3390/molecules24152819
pmc: PMC6695862
pii:
doi:

Substances chimiques

Halogens 0
Histones 0
Radiation-Sensitizing Agents 0
Thiouridine 13957-31-8
4-thio-2'-deoxyuridine 5580-20-1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Narodowe Centrum Nauki
ID : 2014/14/A/ST4/00405
Organisme : Narodowe Centrum Nauki
ID : 2018/28/C/ST4/00479

Références

J Phys Chem A. 2002 Nov 21;106(46):11248-11253
pubmed: 34412195
RSC Adv. 2018 Jun 12;8(38):21378-21388
pubmed: 35539961
Chem Res Toxicol. 2012 Mar 19;25(3):741-6
pubmed: 22303921
Phys Chem Chem Phys. 2015 Jul 14;17(26):16907-16
pubmed: 26059609
Chem Rev. 2004 Jan;104(1):251-61
pubmed: 14719976
Pharmacol Rev. 1977 Dec;29(4):249-72
pubmed: 364496
Org Biomol Chem. 2015 Nov 7;13(41):10362-9
pubmed: 26314288
Int J Mol Sci. 2019 Mar 15;20(6):
pubmed: 30875879
J Photochem Photobiol B. 2015 Apr;145:1-10
pubmed: 25747491
J Phys Chem B. 2015 Jul 2;119(26):8227-38
pubmed: 26061614
J Biol Chem. 2004 Jan 16;279(3):2273-80
pubmed: 14561744
Radiat Res. 1990 Jan;121(1):76-83
pubmed: 2300671
Org Biomol Chem. 2016 Oct 4;14(39):9331-9337
pubmed: 27714271
Curr Mol Med. 2009 May;9(4):442-58
pubmed: 19519402
Rapid Commun Mass Spectrom. 2003;17(20):2279-82
pubmed: 14558126
Transl Oncol. 2011 Aug;4(4):189-98
pubmed: 21804913
Biochemistry. 2005 Feb 15;44(6):1932-40
pubmed: 15697218
Free Radic Biol Med. 2017 Jun;107:101-109
pubmed: 27989755
Radiat Res. 1992 Jul;131(1):90-7
pubmed: 1626053
J Phys Chem A. 2014 Aug 7;118(31):6078-84
pubmed: 25036614
J Chem Phys. 2012 Feb 21;136(7):075101
pubmed: 22360262
J Immunol Methods. 1983 Dec 16;65(1-2):55-63
pubmed: 6606682
Nat Rev Cancer. 2008 Oct;8(10):755-68
pubmed: 18784658
Radiat Res. 1992 Jul;131(1):81-9
pubmed: 1626052
J Chem Phys. 2018 Oct 28;149(16):164307
pubmed: 30384761
J Natl Cancer Inst. 1996 Sep 4;88(17):1193-203
pubmed: 8780628
J Am Chem Soc. 2004 Jan 28;126(3):900-8
pubmed: 14733566
J Phys Chem Lett. 2015 Aug 6;6(15):3091-7
pubmed: 26267207
J Phys Chem B. 2019 Feb 14;123(6):1274-1282
pubmed: 30657689
Int J Radiat Oncol Biol Phys. 1995 Sep 30;33(2):339-48
pubmed: 7673021
J Phys Chem B. 2012 May 17;116(19):5612-9
pubmed: 22510158
J Phys Chem B. 2012 Aug 16;116(32):9676-82
pubmed: 22812492
J Vis Exp. 2011 Mar 13;(49):
pubmed: 21445039
Bioorg Med Chem Lett. 2004 Feb 23;14(4):995-7
pubmed: 15013008
J Phys Chem B. 2017 Jun 29;121(25):6139-6147
pubmed: 28574710

Auteurs

Paulina Spisz (P)

Laboratory of Biological Sensitizers, Faculty of Chemistry, University of Gdańsk, Wita Stwosza 63, 80-308 Gdańsk, Poland.

Magdalena Zdrowowicz (M)

Laboratory of Biological Sensitizers, Faculty of Chemistry, University of Gdańsk, Wita Stwosza 63, 80-308 Gdańsk, Poland.

Samanta Makurat (S)

Laboratory of Biological Sensitizers, Faculty of Chemistry, University of Gdańsk, Wita Stwosza 63, 80-308 Gdańsk, Poland.

Witold Kozak (W)

Laboratory of Biological Sensitizers, Faculty of Chemistry, University of Gdańsk, Wita Stwosza 63, 80-308 Gdańsk, Poland.

Konrad Skotnicki (K)

Centre of Radiation Research and Technology, Institute of Nuclear Chemistry and Technology, Dorodna 16, 03-195 Warsaw, Poland.

Krzysztof Bobrowski (K)

Centre of Radiation Research and Technology, Institute of Nuclear Chemistry and Technology, Dorodna 16, 03-195 Warsaw, Poland.

Janusz Rak (J)

Laboratory of Biological Sensitizers, Faculty of Chemistry, University of Gdańsk, Wita Stwosza 63, 80-308 Gdańsk, Poland. janusz.rak@ug.edu.pl.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH